Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395174 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
A Phase 3 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 870
- Enrollment target
NCT00395174 is a Phase 3 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 870 participants.
The verdict
NCT00395174, a Phase 3 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 870 participants
- Enrollment target
Study Summary
The purpose of this study were to obtain additional evidence in support of the safety and immunogenicity of a recombinant hemagglutinin (rHA) vaccine in an elderly population, and to establish non-inferiority of the immunogenicity of the rHA vaccine when compared with a licensed trivalent influenza vaccine (TIV). Another purpose was to provide a preliminary estimate of the relative efficacy of the two vaccines against culture-positive influenza-like illness during the subsequent epidemic.
Interventions
- BIOLOGICAL Influenza Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395174
The ClinicalTrials.gov registry entry for NCT00395174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 870 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Vaccination is the first listed.
NCT00395174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395174 about?
NCT00395174 is a clinical study titled "Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults". The purpose of this study were to obtain additional evidence in support of the safety and immunogenicity of a recombinant hemagglutinin (rHA) vaccine in an elderly population, and to establish non-inferiority of the immunogenicity of the rHA vaccine when compared with a licensed trivalent influenza ...
What is the current status of trial NCT00395174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 870 participants. The study started on 2006-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00395174?
The interventions under investigation include: Influenza Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT00395174?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.